NDA

July 7, 2017July 7, 2017

SteadyMed Submits New US Drug Application for PAH Treatment Trevyent

News, PAH News

SteadyMed Therapeutics submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Trevyent (treprostinil injection) in the treatment of pulmonary arterial hypertension (PAH), SteadyMed’s partner, Cardiome Pharma, recently announced. ... Read more

May 4, 2017May 4, 2017

SteadyMed’s PatchPump Infusion System for Trevyent Given US Patent

News, PAH News

SteadyMed announced it has received a U.S. patent for its PatchPump infusion system for injectable drugs, including Trevyent, the company’s lead candidate as a potential treatment for pulmonary arterial hypertension (PAH). The patent, issued ... Read more

April 21, 2017April 21, 2017

Patch That Will Deliver Pulmonary Hypertension Treatment Trevyent Is Effective, Study Shows

News, PAH News

The patch that delivers SteadyMed’s pulmonary arterial hypertension (PAH) treatment Trevyent (treprostinil) to patients is effective, safe and tolerable, according to a company study. Treprostinil is a vasodilatory prostacyclin analogue, or synthetic version of prostacyclin, ... Read more

September 8, 2016September 8, 2016

Potential PAH Therapy, Trevyent, Being Readied to Request FDA Approval

News

SteadyMed announced that it recently completed the manufacturing of required batches of its drug candidate Trevyent, designed to treat pulmonary arterial hypertension (PAH). The work will allow the company to evaluate the ... Read more

December 29, 2014October 22, 2015

Actelion Looks to Bring New PAH Drug to Market

News

Biopharmaceutical company and leader in pulmonary arterial hypertension (PAH) therapeutics, Actelion Ltd., has just announced it has filed a New Drug Application (NDA) with the US Food and Drug ... Read more